Episode summary

MRNA Plunges 20% in Two Days: Leak Shows Positive Cancer Vaccine Trial Results

Schwab Network · · Guests: Alison Kosik, Tim Biggam

MRNA Plunges 20% in Two Days: Leak Shows Positive Cancer Vaccine Trial Results – Schwab Network

Summary

Moderna shares were hit by a sharp selloff after a partial leak of clinical-trial data for its personalized cancer vaccine with Merck, even though the full readout released Thursday appeared positive. The host said the stock had fallen 25% yesterday and was still under pressure around $200.50, after trading was halted because of the volatility. Alison Kosik explained that the leaked information reached social media before the planned weekend presentation at the European Society for Medical Oncology, forcing the full data onto the website and then into the market early.

The key result in the released data was a 42% reduction in the risk of recurrence or death in certain melanoma patients versus Keytruda alone. Kosik said the reaction looked like a “sell the news” move because Moderna had already risen more than 500% this year, and Wall Street had built in very high expectations. She also noted that multiple trials in solid tumors are still underway, so investors may keep trading around each new update rather than resetting the story from one data release.

Tim Biggam said he expected Moderna to stay in a wide trading range over the next month, and he suggested an iron condor to collect premium from that expected volatility. He also tied the broader market to oil, Treasury yields, and geopolitical risk, saying stocks could struggle if oil stays elevated and Iran-related tensions persist.

Key takeaways

  • Alison Kosik said the full data on Moderna’s cancer vaccine looked positive, but the leak sparked a “sell the news” reaction anyway.
  • Kosik said the released data showed a 42% reduction in recurrence or death in certain melanoma patients when combined with Merck’s Keytruda.
  • The host said Moderna fell 25% yesterday and was still under pressure after trading was halted for volatility.
  • Tim Biggam expected Moderna to stay in a wide range and proposed a November iron condor for about a $1.70 net credit.
  • Biggam said the broader market is still being driven mainly by oil, with rates and Iran-related tensions also in focus.

Notable quotes

“There appears to be sell the news reaction pl out here, noting that as you kind of said, Sam, that the shares remain up over 500% this year”

— A speaker on Schwab Network at 2:41

“So implied volatility is still very high, albeit a little bit lower”

— A speaker on Schwab Network at 4:49

“I think the market will have trouble heading appreciably higher going fo unless we see oil come down”

— A speaker on Schwab Network at 6:53

Topics

  • cancer vaccine trial results
  • moderna stock drop
  • leaked clinical data
  • options trading example
  • market expectations correction

Companies and tickers mentioned

  • MRNA
  • Moderna

Watch the episode

Watch “MRNA Plunges 20% in Two Days: Leak Shows Positive Cancer Vaccine Trial Results” on YouTube

Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.

More from Schwab Network

All Schwab Network episodes →

Schwab Network, this episode and its artwork belong to their owners. Octagon is not affiliated with the show; this page is an independent summary.